Mechanism of Action
PAC1 Receptor and cAMP Signaling
PAC1 receptor activation by PACAP-38 stimulates adenylate cyclase via Gs coupling, elevating intracellular cAMP. cAMP activates PKA, which phosphorylates CREB (cAMP-response element binding protein), the master transcription factor for neuronal survival, BDNF expression, and synaptic plasticity genes. PKA also activates Epac (exchange protein directly activated by cAMP), a cAMP sensor that activates Rap1 GTPase and downstream pro-survival signaling. In neurons, elevated cAMP reduces pro-apoptotic signaling (reduced cytochrome c release, reduced caspase-3 activation) and promotes mitochondrial biogenesis via PGC-1alpha.
Multi-modal Neuroprotection
PACAP-38's neuroprotection is multi-layered. Anti-excitotoxic: reduces NMDA receptor-mediated glutamate toxicity by reducing calcium influx. Anti-inflammatory: decreases microglial NF-kB activation and reduces TNF-alpha, IL-1beta, and IL-6 secretion in activated microglia. Anti-apoptotic: upregulates Bcl-2 and XIAP, downregulates Bax and caspase-3. Neurotrophic: stimulates BDNF, GDNF, and NT-3 synthesis in both neurons and glia. Mitochondrial protection: maintains mitochondrial membrane potential under oxidative stress conditions. This combination makes PACAP-38 one of the most comprehensive neuroprotective compounds in the preclinical literature.
Migraine Mechanism
IV PACAP-38 reliably induces migraine attacks in migraineurs but not controls. This occurs via PAC1/VPAC1 receptor activation on trigeminal sensory neurons, promoting release of CGRP (alpha-cgrp/" class="wiki-internal-link">calcitonin gene-related peptide) and neurogenic dilation of meningeal vessels. PAC1 receptor antagonists (AMG 301, ALD1910) are in Phase II trials for migraine prevention. The migraine-inducing property has made intranasal or SC delivery preferable to IV for neuroprotection research, as peripheral exposure at lower doses is less likely to trigger this response.
Research Summary
Neuroprotection in Ischemia and Neurodegeneration
Strong EvidenceIntranasal PACAP-38 reduces infarct volume by 30-60% in rodent middle cerebral artery occlusion (MCAO) stroke models, among the largest effects of any neuroprotective agent tested in these models. In Parkinson's disease models (6-OHDA, MPTP), PACAP-38 prevents dopaminergic neuron loss and preserves motor function. In ALS models, PACAP-38 delays motor neuron death and extends survival. The preclinical data is exceptionally consistent, though human translation has been limited by delivery challenges and the IV migraine-triggering effect.
PTSD and Stress Biology
EmergingRessler et al (2011, Nature) identified a PACAP/PAC1 receptor single nucleotide polymorphism in the estrogen response element of the PAC1 gene that predicts PTSD risk in women exposed to trauma, one of the first genetic associations for sex-specific PTSD risk. Plasma PACAP-38 levels are elevated in PTSD women and correlate with fear symptom severity and physiological startle responses. This positions PACAP signaling as a potential therapeutic target in PTSD, though whether to increase or decrease PACAP activity may be context- and sex-dependent.
TBI and Spinal Cord Injury
Moderate EvidenceIntranasal PACAP-38 administered within 6 hours of experimental TBI significantly reduces axonal damage, white matter injury, and long-term behavioral deficits in mouse models. In spinal cord injury models, local PACAP delivery reduces secondary injury cascade and improves hind limb function recovery. The therapeutic window (effective up to 6 hours post-injury) is more clinically actionable than many neuroprotective agents.
Calculate your PACAP-38 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuroprotection / acute injury | 300-600 mcg intranasal | Twice daily for 1-4 weeks | Intranasal (preferred for CNS delivery) |
| Cognitive / neuroplasticity support | 200-400 mcg SC | Daily or EOD | Subcutaneous |
| Post-TBI protocol | 400 mcg intranasal | Every 6-8 h first 72 h; then daily for 2 weeks | Intranasal |
Avoid IV delivery of PACAP-38 due to reliable migraine induction in susceptible individuals. Intranasal is the preferred research route for CNS-targeted applications. PACAP-38 degrades rapidly, prepare fresh solutions and use within 24-48 h of reconstitution at 4 C. PACAP-27 (truncated form) has similar neuroprotective activity and is sometimes used as an alternative.
Interactions
Safety Profile
The principal safety concern with PACAP-38 is migraine induction with IV administration in susceptible individuals (migraineurs). Intranasal delivery at research doses is much less likely to cause this response due to lower peak plasma levels. In non-migraineurs, IV PACAP-38 causes flushing, mild hypotension, and tachycardia at doses above 10 pmol/kg/min infusion. Intranasal administration at typical research doses is generally well-tolerated with mild nasal irritation reported. The vasodilatory effect means PACAP-38 should be used with caution in hypotension or cardiovascular instability. Not WADA prohibited. Not scheduled.
References
- [1]Miyata A et al. "Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells." Biochem Biophys Res Commun. 1989;164(1):567-574.
- [2]Ressler KJ et al. "Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor." Nature. 2011;470(7335):492-497.
- [3]Toth D et al. "PACAP-38 and PACAP(6-38) both inhibit the neuronal activity in the central amygdala." Peptides. 2012;38(2):394-399.